Praxis Precision Medicines Inc has a consensus price target of $122.56 based on the ratings of 10 analysts. The high is $270 issued by Piper Sandler on July 1, 2024. The low is $4 issued by B of A Securities on June 7, 2022. The 3 most-recent analyst ratings were released by Piper Sandler, Needham, and Guggenheim on July 1, 2024, June 24, 2024, and June 18, 2024, respectively. With an average price target of $190 between Piper Sandler, Needham, and Guggenheim, there's an implied 223.96% upside for Praxis Precision Medicines Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
07/01/2024 | Buy Now | 360.36% | Piper Sandler | Yasmeen Rahimi | $270 → $270 | Maintains | Overweight | Get Alert |
06/24/2024 | Buy Now | 147.23% | Needham | Ami Fadia | → $145 | Initiates | → Buy | Get Alert |
06/18/2024 | Buy Now | 164.28% | Guggenheim | Yatin Suneja | → $155 | Initiates | → Buy | Get Alert |
05/16/2024 | Buy Now | 155.75% | Truist Securities | Joon Lee | $150 → $150 | Maintains | Buy | Get Alert |
05/14/2024 | Buy Now | 79.03% | HC Wainwright & Co. | Douglas Tsao | → $105 | Reiterates | Buy → Buy | Get Alert |
05/01/2024 | Buy Now | 99.49% | Baird | Joel Beatty | → $117 | Initiates | → Outperform | Get Alert |
04/26/2024 | Buy Now | 79.03% | HC Wainwright & Co. | Douglas Tsao | → $105 | Reiterates | Buy → Buy | Get Alert |
03/26/2024 | Buy Now | 79.03% | HC Wainwright & Co. | Douglas Tsao | → $105 | Reiterates | Buy → Buy | Get Alert |
03/26/2024 | Buy Now | 118.24% | Jefferies | Kambiz Yazdi | $75 → $128 | Maintains | Buy | Get Alert |
03/06/2024 | Buy Now | 79.03% | HC Wainwright & Co. | Douglas Tsao | → $105 | Reiterates | Buy → Buy | Get Alert |
01/12/2024 | Buy Now | -50.55% | Wedbush | Laura Chico | $16 → $29 | Maintains | Neutral | Get Alert |
12/05/2023 | Buy Now | 79.03% | HC Wainwright & Co. | Douglas Tsao | → $105 | Reiterates | Buy → Buy | Get Alert |
12/04/2023 | Buy Now | 155.75% | Truist Securities | Joon Lee | → $150 | Reiterates | Buy → Buy | Get Alert |
11/15/2023 | Buy Now | -88.06% | HC Wainwright & Co. | Douglas Tsao | → $105 | Reiterates | Buy → Buy | Get Alert |
10/03/2023 | Buy Now | -96.59% | Wedbush | Laura Chico | → $30 | Reiterates | Neutral → Neutral | Get Alert |
09/19/2023 | Buy Now | -82.95% | Truist Securities | Joon Lee | → $150 | Initiates | → Buy | Get Alert |
08/10/2023 | Buy Now | -88.06% | HC Wainwright & Co. | Douglas Tsao | $225 → $105 | Maintains | Buy | Get Alert |
08/09/2023 | Buy Now | -74.42% | HC Wainwright & Co. | Douglas Tsao | → $225 | Reiterates | Buy → Buy | Get Alert |
06/20/2023 | Buy Now | -96.59% | Wedbush | Laura Chico | → $30 | Reiterates | Neutral → Neutral | Get Alert |
06/12/2023 | Buy Now | -74.42% | HC Wainwright & Co. | Douglas Tsao | → $225 | Reiterates | Buy → Buy | Get Alert |
06/02/2023 | Buy Now | -93.18% | Jefferies | Kambiz Yazdi | → $60 | Initiates | → Buy | Get Alert |
05/12/2023 | Buy Now | -96.59% | Wedbush | Laura Chico | → $30 | Reiterates | → Neutral | Get Alert |
05/12/2023 | Buy Now | -74.42% | HC Wainwright & Co. | Douglas Tsao | → $225 | Reiterates | Buy → Buy | Get Alert |
04/14/2023 | Buy Now | -72.72% | HC Wainwright & Co. | Douglas Tsao | → $240 | Reiterates | → Buy | Get Alert |
03/06/2023 | Buy Now | — | William Blair | Myles Minter | — | Downgrade | Outperform → Market Perform | Get Alert |
03/06/2023 | Buy Now | -72.72% | HC Wainwright & Co. | Douglas Tsao | → $240 | Reiterates | → Buy | Get Alert |
02/08/2023 | Buy Now | -72.72% | HC Wainwright & Co. | Douglas Tsao | → $240 | Reiterates | → Buy | Get Alert |
02/03/2023 | Buy Now | -72.72% | HC Wainwright & Co. | Douglas Tsao | → $240 | Reiterates | → Buy | Get Alert |
06/08/2022 | Buy Now | -69.31% | Piper Sandler | Yasmeen Rahimi | $975 → $270 | Maintains | Overweight | Get Alert |
06/07/2022 | Buy Now | -82.95% | HC Wainwright & Co. | Douglas Tsao | $720 → $150 | Maintains | Buy | Get Alert |
06/07/2022 | Buy Now | -93.18% | B of A Securities | Tazeen Ahmad | $390 → $60 | Downgrade | Buy → Neutral | Get Alert |
12/16/2021 | Buy Now | -18.16% | HC Wainwright & Co. | Douglas Tsao | → $720 | Initiates | → Buy | Get Alert |
08/26/2021 | Buy Now | -52.26% | B of A Securities | Tazeen Ahmad | → $420 | Initiates | → Buy | Get Alert |
The latest price target for Praxis Precision Medicine (NASDAQ:PRAX) was reported by Piper Sandler on July 1, 2024. The analyst firm set a price target for $270.00 expecting PRAX to rise to within 12 months (a possible 360.36% upside). 18 analyst firms have reported ratings in the last year.
The latest analyst rating for Praxis Precision Medicine (NASDAQ:PRAX) was provided by Piper Sandler, and Praxis Precision Medicine maintained their overweight rating.
There is no last upgrade for Praxis Precision Medicine
The last downgrade for Praxis Precision Medicines Inc happened on March 6, 2023 when William Blair changed their price target from N/A to N/A for Praxis Precision Medicines Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Praxis Precision Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Praxis Precision Medicine was filed on July 1, 2024 so you should expect the next rating to be made available sometime around July 1, 2025.
While ratings are subjective and will change, the latest Praxis Precision Medicine (PRAX) rating was a maintained with a price target of $270.00 to $270.00. The current price Praxis Precision Medicine (PRAX) is trading at is $58.65, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.